ReviewJournal of genetics2009
Channelrhodopsins provide a breakthrough insight into strategies for curing blindness.
Review in Journal of genetics, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Properties of a Single Amino Acid Residue in the Third Transmembrane Domain Determine the Kinetics of Ambient Light-Sensitive Channelrhodopsin.International journal of molecular sciences · 2023Article
- Development of an optogenetic gene sensitive to daylight and its implications in vision restoration.NPJ Regenerative medicine · 2021Article
- Control of Brain State Transitions with a Photoswitchable Muscarinic Agonist.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2021Article
- Visual Responses of Photoreceptor-Degenerated Rats Expressing Two Different Types of Channelrhodopsin Genes.Scientific reports · 2017Article
- Local and systemic responses following intravitreous injection of AAV2-encoded modified Volvox channelrhodopsin-1 in a genetically blind rat model.Gene therapy · 2016Article
- Optogenetic control of insulin secretion by pancreatic β-cells in vitro and in vivo.Gene therapy · 2015Article
- Restoration of the majority of the visual spectrum by using modified Volvox channelrhodopsin-1.Molecular therapy : the journal of the American Society of Gene Therapy · 2014Article
- Proceedings of the First International Optogenetic Therapies for Vision Symposium.Translational vision science & technology · 2013Article
- Channelrhodopsins: visual regeneration and neural activation by a light switch.New biotechnology · 2013Review
- Cell replacement and visual restoration by retinal sheet transplants.Progress in retinal and eye research · 2012Review
- Diversity of Chlamydomonas channelrhodopsins.Photochemistry and photobiologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Photoreceptor cells are the only retinal neurons that can absorb photons. Their degeneration due to some diseases or injuries leads to blindness. Retinal prostheses electrically stimulating surviving retinal cells and evoking a pseudo light sensation have been investigated over the past decade for restoring vision. Currently, a gene therapy approach is under development. Channelrhodopsin-2 derived from the green alga Chlamydomonas reinhardtii, is a microbial-type rhodopsin. Its specific characteristic is that it functions as a light-driven cation-selective channel. It has been reported that the channelrhodopsin-2 transforms inner light-insensitive retinal neurons to light-sensitive neurons. Herein, we introduce new strategies for restoring vision by using channelrhodopsins and discuss the properties of adeno-associated virus vectors widely used in gene therapy.
Indexed as
Identifiers
20090204What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.